で公開中です！ 詳しく見る
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

上場廃止済み

MRTXは2024年1月22日に上場廃止となりました。

ランキングに戻る
 

概要： Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

従業員数： 593

ヘルスケア 医薬品メーカー（総合）

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 0%
ネガティブ 0%
ポジティブ
Zacks Investment Research
2 年前
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
ニュートラル
PRNewsWire
2 年前
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previously received treatment with a platinum-based regimen and an immune checkpoint inhibitor.
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
ポジティブ
CNBC
2 年前
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
ポジティブ
Zacks Investment Research
2 年前
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています